- Policy
- The selection of benefit revaluation is approaching
- by Lee, Hye-Kyung Feb 14, 2022 05:54am
- The pharmaceutical industry has suggested that it is difficult to review and predict the criteria for selecting evaluation targets as the targets for benefit revaluation were disclosed in the current year during the pilot project of Choline alfoscerate and Bilberry Fruit Dried Ext, Avocado-Soya, Ginkgo Leaf Ext, Silymarin, and Vitis Vinifera. I
- Company
- Successful renewal of RSA contract for Keytruda
- by Eo, Yun-Ho Feb 11, 2022 05:56am
- Keytruda, an immuno-cancer drug, succeeded in renewing its RSA contract for the first time in half a year. According to related industries, MSD Korea signed an RSA renewal with the NHIS last month for indications such as NSCLC therapy, which is currently covered by PD-1 low-release Keytruda. Keytruda, which contract expired in August la
- Policy
- Bill to stop reimbursement of drugs upon disposition
- by Lee, Jeong-Hwan Feb 11, 2022 05:55am
- A bill to immediately stop prescriptions of pharmaceuticals that have received sales suspension dispositions due to expedient acts such as rebates at hospitals and clinics is being pushed for legislation. If enacted, the bill will immediately suspend reimbursement of pharmaceuticals that will receive administrative dispositions and stop h
- Company
- Prodrug for Forxiga patent dispute ruling has been postponed
- by Kim, Jin-Gu Feb 11, 2022 05:55am
- The second trial ruling on the patent dispute between Dong-A ST and AstraZeneca over Forxiga, a diabetes treatment based on SGLT-2 inhibitors, has been postponed. The Patent Court's 5-2 Court postponed the date of the judgment on the trial decision cancellation suit filed by AstraZeneca against Dong-A ST from the 10th to the 17th. The cour
- Policy
- “Will provide systemic support for homegrown mRNA vaccines"
- by Lee, Hye-Kyung Feb 11, 2022 05:55am
- The Ministry of Food and Drug Safety promised to spare no effort in providing institutional support so that domestic companies can foster mRNA vaccine manufacturing and development capabilities. On the 9th, Food and Drug Safety Minister Gang-lip Kim held a roundtable meeting with vaccine R&D developers and experts that are participating
- Policy
- It's hard to handle free national support for self-diagnosis
- by Lee, Jeong-Hwan Feb 11, 2022 05:55am
- Prime Minister Kim Bu-Gyeom expressed disapproval of the ruling party's proposed "free support for self-diagnosis kits for the whole country." This is because the production of diagnostic kits is currently insufficient to cover free distribution across the country. On the 8th, Prime Minister Kim responded to a question from Rep. Shin Hyun-
- Opinion
- [Desk] 550,000 soldiers and COVID-19 vaccine
- by Nho, Byung Chul Feb 10, 2022 05:54am
- In mid-August last year, the Ministry of National Defense completed the first and second vaccinations against 550,000 soldiers. The types are identified as Moderna and Pfizer vaccines, including the Janssen vaccine. It deserves to be evaluated as a "successful vaccine operation" achieved quickly in a quasi-war situation facing North Korea. Cu
- Company
- Skyrizi adds psoriatic arthritis indication
- by Feb 10, 2022 05:54am
- Abbvie’s ‘Skyrizi’ has expanded its indication to psoriatic arthritis. As the fourth interleukin inhibitor to receive approval for the indication, Skyrizi has set out to overtake the market with its convenience in administration. On the 9th, Abbvie Korea has held a ‘Press Conference to celebrate Skyrizi’s indication expansion to psor
- Company
- SK Bioscience releases second batch of COVID-19 vaccines
- by Kim, Jin-Gu Feb 10, 2022 05:54am
- SK Bioscience announced that it had shipped its second batch of commercial COVID-19 vaccine products. By manufacturing vaccines for AstraZeneca and then Novavax, the industry's evaluation is that the company has well demonstrated its large-scale and stable manufacturing capacity. SK Bioscience announced that it had shipped the first batch
- Company
- Effect of the release of generics for Tamsulosin
- by Ji Yong Jun Feb 10, 2022 05:54am
- The size of the Tamsulosin market, a treatment for prostatic hypertrophy, has soared. The market is also expanding as the influence of generic products has increased since the patent expired in 2015. According to UBIST, a pharmaceutical market research firm, on the 5th, Tamsulosin's outpatient prescription amount last year was 191.2 billion w
